Neurotensin Receptor Inhibitor

AF38469 is a selective, orally bioavailable Sortilin inhibitor with an IC₅₀ value of 330 nM.

VGD020 is a highly potent and selective Sec61 translocon inhibitor. VGD020 suppresses the expression of cell surface CD4 by inhibiting signal peptide-dependent co-translational ER translocation, interferes with the initiation of ER translocation of dengue virus polyprotein, and reduces the expression of Sortilin in breast cancer cells. VGD020 exhibits broad anti-flavivirus and anti-HIV activities. VGD020 can be used in research related to dengue virus infection, Zika virus infection, yellow fever virus infection, human immunodeficiency virus infection, and breast cancer.

Latozinemab (AL001) is a recombinant human anti-Sortilin monoclonal antibody. Latozinemab effectively binds Sortilin with a high affinity and blocks the interaction between progranulin protein (PGRN) and Sortilin receptor. Latozinemab has the potential for progranulin gene (GRN) mutations causative of Frontotemporal dementia (FTD) (FTD-GRN) research.

SORT-PGRN interaction inhibitor 1 is a potent inhibitor of the sortilin-progranulin interaction with an IC₅₀ of 2 μM.

BVFP binds to the PGRN_588–593 peptide with a K_d of 20 μM. BVFP can disrupt PGRN-SORT1 binding. BVFP also inhibits SORT1-mediated rPGRN endocytosis.

AF40431, the first reported small-molecule ligand of sortilin, has an IC₅₀ of 4.4 µM and a K_d of 0.7 µM . AF40431 is bound in the neurotensin-binding site of sortilin.

NTSR1 Human Pre-designed siRNA Set A contains three designed siRNAs for NTSR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SORT-PGRN interaction inhibitor 3 (Compound 13) is a SORT-PGRN interaction inhibitor (IC₅₀: 0.17 μM). SORT-PGRN interaction inhibitor 3 can be used for research of neurodegenerative diseases.

Ntsr1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ntsr1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

SORT-PGRN interaction inhibitor 2 is a SORT-PGRN inhibitor that can decreases SORT1 protein expression and increases extracellular PGRN secretion in mammalian cell lines. SORT-PGRN interaction inhibitor 2 can be used for neurological disease research.

VGD071, a sortilin-targeting compound, is a promising candidate for future studies using mouse breast cancer models.

Ntsr1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ntsr1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

SORT1-IN-3 (compound 5) is a blood-brain barrier permeable SORT1 inhibitor.

SORT1-IN-1 (compound 2) is a SORT1 inhibitor.

SORT1-IN-5 (compound 3) is a blood-brain barrier permeable SORT1 inhibitor. SORT1-IN-5 is an MSOH salt with limited oral bioavailability.

Ntsr2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ntsr2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ntsr2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ntsr2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

NTSR2 Human Pre-designed siRNA Set A contains three designed siRNAs for NTSR2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SORT1-IN-4 (compound 6) is a blood-brain barrier permeable SORT1 inhibitor.

SORT1-IN-2 (compound 6) is a SORT1 inhibitor.